CTOs on the Move

Biomet

www.biomet.com

 
Biomet, Inc. is one of the world's leading medical device manufacturers located in the Warsaw, Indiana business cluster. The company specializes in reconstructive products for hips, knees and shoulders, fixation devices, orthopedic support devices, dental implants, spinal implants and operating room supplies.   Biomet was established in 1977 and delivered its first hip replacement in 1978. In a September 2007 club deal the company was acquired by a consortium of private equity firms and ceased trading on NASDAQ.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.biomet.com
  • 56 E Bell Dr
    Warsaw, IN USA 46582
  • Phone: 574.267.6639

Executives

Name Title Contact Details

Similar Companies

Qserve America

Qserve America is a Claremont, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accelmed Growth Partners

Accelmed is an investment firm focused on value creation for medical device companies and technologies. Accelmed was founded in 2009 by Mori Arkin and Uri Geiger and invests in small and mid-cap private and public companies.

Applied Medical Technology

Applied Medical Technology is a Brecksville, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CoorsTek Medical

At CoorsTek Medical, our vision is to make lives measurably better. We are the partner of choice for medical innovators and medical-device providers worldwide whose success requires access to leading-edge medical device development experts and the related set of specialized product development and manufacturing capabilities.

TriVascular

TriVascular has pioneered numerous design and manufacturing technologies in pursuit of our commitment to providing optimal solutions for endovascular aortic repair (EVAR). TriVascular`s initial product offerings are novel endovascular grafts focused on significantly advancing EVAR. Building upon partnerships with thought leading clinicians worldwide, TriVascular`s products are designed to address unmet clinical needs and expand the pool of patients who are candidates for EVAR.